Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by K. Izutsu
Augment: Relapsed/Refractory Indolent NHL Patients Were More Sensitive to Next Treatment Following Lenalidomide/Rituximab (R2 ) Than Rituximab/Placebo
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Augment Phase Iii Study: Lenalidomide/Rituximab (R2 ) Improved Efficacy Over Rituximab/Placebo in Relapsed/Refractory Follicular Patients Irrespective of Pod24 Status
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Intravenous Immunoglobulin Therapy Use in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated With Tisagenlecleucel in the Juliet Trial
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Aggressive Natural Killer Cell Leukemia: A Nationwide Multicenter Analysis in Japan
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Allogeneic Hematopoietic Stem Cell Transplantation for Primary Mediastinal Large B-Cell Lymphoma Patients Relapsing After High Dose Chemotherapy With Autologous Stem Cell Transplantation: Data From the Japan Society for Hematopoietic Cell Transplantation
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
The Role of Surveillance Computed Tomography in Patients With Follicular Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN RELAPSED/REFRACTORY (R/R) INDOLENT NHL IN THE PHASE 3 AUGMENT TRIAL OF RITUXIMAB (R) PLUS LENALIDOMIDE (R2 ) VERSUS R PLUS PLACEBO
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Clinical Significance of Uptake Value on F18-FDG Pet/Ct and Histological Grade in 164 Patients With Follicular Lymphoma Including Transformation - A Single Center Retrospective Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Post Hoc Analyses of Patients With Relapsed/Refractory Marginal Zone Lymphoma Who Received Lenalidomide Plus Rituximab (R2 ) vs Rituximab/Placebo (Augment)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
ROBUST: First Report of Phase III Randomized Study of Lenalidomide/R-Chop (R2 -CHOP) vs Placebo/R-Chop in Previously Untreated ABC-type Diffuse Large B-Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
1
2
›
